Literature DB >> 16138997

Central retinal artery occlusion: visual outcome.

Sohan Singh Hayreh1, M Bridget Zimmerman.   

Abstract

PURPOSE: To investigate systematically the natural history of visual outcome in central retinal artery occlusion (CRAO).
DESIGN: Cohort study.
METHODS: At entry, 244 consecutive patients (260 eyes) with CRAO (seen consecutively from 1973 to 2000) had a detailed ocular and medical history and ocular evaluation. CRAO eyes were classified into four categories: non-arteritic (NA) CRAO (171 eyes), NA-CRAO with cilioretinal artery sparing (35), transient NA-CRAO (41), and arteritic CRAO (13).
RESULTS: Within 7 days of onset of CRAO, initial visual acuity differed among the four CRAO types (P < .0001). In eyes with vision of counting fingers or worse, it improved in 82% of eyes with transient NA-CRAO, 67% of eyes with NA-CRAO with cilioretinal artery sparing, and 22% of eyes with NA-CRAO. Visual acuity improved primarily within the first 7 days (P < .0001). In the central 30-degree visual field, central scotoma was most common. Central visual field improved in 39% with transient NA-CRAO, 25% with NA-CRAO with cilioretinal artery sparing, and 21% with NA-CRAO. Peripheral visual field was normal in 62.9% of eyes with transient NA-CRAO and 22.1% in those with NA-CRAO. In 51.9% of eyes with NA-CRAO, the only remaining visual field was a peripheral island. Peripheral fields improved in NA-CRAO (39%) and in transient NA-CRAO (39%).
CONCLUSIONS: Classification of CRAO is crucial for understanding differences in visual outcome. Marked improvement in visual acuity and visual field can occur without treatment and is determined by several factors. Visual field information is essential to evaluate visual disability in CRAO.

Entities:  

Mesh:

Year:  2005        PMID: 16138997     DOI: 10.1016/j.ajo.2005.03.038

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  102 in total

1.  Natural history of visual outcome in central retinal vein occlusion.

Authors:  Sohan Singh Hayreh; Patricia A Podhajsky; M Bridget Zimmerman
Journal:  Ophthalmology       Date:  2010-08-17       Impact factor: 12.079

2.  Comment re: multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications.

Authors:  Sohan Singh Hayreh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-22       Impact factor: 3.117

3.  Surgical embolus removal in retinal artery occlusion.

Authors:  Sohan Singh Hayreh
Journal:  Br J Ophthalmol       Date:  2007-08       Impact factor: 4.638

4.  Central retinal artery occlusion and cerebral stroke.

Authors:  D McLeod
Journal:  Eye (Lond)       Date:  2013-10-04       Impact factor: 3.775

5.  Retinal vascular occlusions: an interdisciplinary challenge.

Authors:  Alireza Mirshahi; Nicolas Feltgen; Lutz L Hansen; Lars-Olof Hattenbach
Journal:  Dtsch Arztebl Int       Date:  2008-06-27       Impact factor: 5.594

6.  Central retinal artery occlusion due to paroxysmal atrial fibrillation: the importance of Holter monitoring.

Authors:  C Kirwan; D Sugrue; M O'Keefe
Journal:  Ir J Med Sci       Date:  2008-05-01       Impact factor: 1.568

Review 7.  Ocular vascular occlusive disorders: natural history of visual outcome.

Authors:  Sohan Singh Hayreh
Journal:  Prog Retin Eye Res       Date:  2014-04-21       Impact factor: 21.198

Review 8.  Retinal Diseases that Can Masquerade as Neurological Causes of Vision Loss.

Authors:  Tanyatuth Padungkiatsagul; Loh-Shan Leung; Heather E Moss
Journal:  Curr Neurol Neurosci Rep       Date:  2020-09-15       Impact factor: 5.081

9.  Thrombolysis for acute central retinal artery occlusion: is it time?

Authors:  Valérie Biousse
Journal:  Am J Ophthalmol       Date:  2008-11       Impact factor: 5.258

10.  Circadian incidence of non-inflammatory retinal artery occlusions.

Authors:  Dieter Schmidt; Martin Schumacher; Nicolas Feltgen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-07       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.